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Epitope Enhancement of a CD4 HIV Epitope toward the
Development of the Next Generation HIV Vaccine1
Takahiro Okazaki,2* C. David Pendleton,* Pablo Sarobe,3* Elaine K. Thomas,4†
Sujatha Iyengar,‡ Clayton Harro,‡ David Schwartz,‡ and Jay A. Berzofsky5*
Virus-specific CD4 T cell help and CD8 cytotoxic T cell responses are critical for maintenance of effective immunity in chronic
viral infections. The importance of CD4 T cells has been documented in HIV infection. To investigate whether a stronger CD4
T cell response can be induced by modifications to enhance the T1 epitope, the first CD4 T cell epitope discovered in HIV-1-
gp120, we developed a T1-specific CD4 T cell line from a healthy volunteer immunized with a canarypox vector expressing gp120
and boosted with recombinant gp120. This T1-specific CD4 T cell line was restricted to DR13, which is common in U.S.
Caucasians and African-Americans and very frequent in Africans. Peptides with certain amino acid substitutions in key positions
induced enhanced specific CD4 T cell proliferative responses at lower peptide concentration than the original epitope. This
relatively conserved CD4 epitope improved by the epitope enhancement strategy could be a component of a more effective second
generation vaccine construct for HIV infection. The Journal of Immunology, 2006, 176: 3753–3759.
T he CD4 T cell help plays a critical role in maintainingCTL function in viral infection (1–5). In HIV-infectedpatients, a quantitative decline in the number of CD4
lymphocytes and a qualitative impairment of CD4 T cell function
lead to AIDS. However, the HIV-specific CD4 T cell response
can be recovered after initiation of highly active antiretroviral ther-
apy. This recovery is inversely correlated with HIV viral load (5,
6). In mice, CD4 T cells are required for expansion and memory
of CD8 CTLs (7–9), suggesting that stronger CD4 T cell help
is required for the maintenance of CTL and control of viremia.
Furthermore, these facts suggest the hypothesis that the immune
response induced by HIV infection might be insufficient, in part
due to the evolution of HIV epitopes under immune selective pres-
sure to evade the immune response. Therefore, the virus might be
controlled by a vaccine incorporating improved CD4 epitopes
substituted at some amino acid positions to induce a stronger
CD4 T cell response for helping HIV-specific CTL proliferation,
together with similarly enhanced CTL epitopes. This approach of
epitope enhancement could enable us to develop a more effective
HIV vaccine (10–12). Whereas epitope enhancement has been ap-
plied to several peptides binding class I HLA molecules, there is
little experience doing so for epitopes binding to class II HLA
molecules for which binding motifs are less well defined.
The T1 Ag is a 16-mer peptide (KQIINMWQEVGKAMYA)
CD4 epitope that was the first helper epitope discovered in the HIV
envelope protein (13). Immunization with this peptide can induce
an epitope-specific CD4 response in mice (restricted to H-2b, H-2d,
H-2k, and H-2s (14, 15)), and the same epitope is recognized by
human T cells from HIV-infected or immunized individuals (16,
17). Furthermore, a gain in potency for CD4 response is observed
when 436E (glutamic acid) in the T1 epitope is replaced with A
(alanine) in mice (18–20), suggesting that substitution of residues
that interfere with binding might allow the design of a more potent
vaccine. However, this substitution of residues enhances binding
to one murine class II MHC molecule. Little is known about the
HLA class II restriction of this epitope in humans. We, therefore,
wanted to identify other amino acid substitutions that would im-
prove presentation by human class II HLA molecules, to design a
more effective vaccine. For this reason, we developed a T1-specific
CD4 T cell line from a healthy volunteer immunized with a ca-
narypox virus vector expressing HIV gp120 and boosted with
rgp120. Using this human CD4 T cell line restricted by an
HLA-DR molecule common in both the United States and Africa,
we show the possibility of inducing a stronger HIV-specific CD4
T cell response by stimulation with an epitope-enhanced T1 pep-
tide. This may be a valuable component of a second generation
HIV vaccine.
Materials and Methods
Synthetic peptide
Peptides were prepared in an automated multiple peptide synthesizer (Sym-
phony; Protein Technologies) using F-moc chemistry. They were purified
by reverse-phase HPLC, and their sequences were confirmed, where
needed, on an automated sequencer (477A; Applied Biosystems) or by
amino acid analysis. Peptide purity was determined by a single peak on
reverse-phase HPLC, and by amino acid analysis. Where necessary, se-
quencing and/or mass spectrometry were also performed.
Immunized blood donor
The healthy HIV-negative volunteer, JO22A304X, had been immunized
previously with a canarypox virus vector expressing HIV gp120 as part of
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AVEG clinical protocol 022A. Human studies were approved by an ap-
propriate institutional review board, and were conducted with the informed
consent of the subject. Briefly, the blood donor was immunized with AL-
VAC (vCP205) at months 0 and 1 and was boosted with ALVAC and
Chiron’s rgp120 at months 3, 6, 9, and 12. Chiron’s rgp120 has the T1 Ag
of the SF2 strain of HIV-1, whose amino acid sequence is
KQIINMWQEVGKAMYA,
Monocyte-derived dendritic cell preparation
After thawing frozen stocks of PBMCs from the donor, 5  106 PBMCs
were cultured with 1000 U/ml human GM-CSF and 1000 U/ml human IL-4
in a 6-well culture plate in RPMI 1640 medium containing 10% autologous
plasma. Human GM-CSF and human IL-4 were added every other day to
grow out dendritic cells. After pulsing with an appropriate concentration of
peptide, 3 g/ml soluble CD40-ligand (provided by E. Thomas, Immunex,
Seattle, WA) was added to the culture at day 4 to mature the dendritic cells.
Maturation of dendritic cells was confirmed by up-regulation of CD83
measured by flow cytometry. The next day, after being harvested, irradi-
ated with 10,000 rad, and washed three times, the cultured cells enriched
in monocyte-derived dendritic cells were used as an APC source for T cell
culture development and maintenance. However, peptide pulsing was not
done in the preparation of these APCs for proliferation assays; rather, sol-
uble peptide was titrated in the wells with the APCs and T cells in the
culture.
Generation of peptide-specific CD4 T cell line
A total of 5  105/well freshly isolated PBMCs obtained from the healthy
donor immunized with a canarypox virus vector expressing HIV gp120 and
boosted with rgp120 was cultured with 3 M T1 peptide in 96-well U-
bottom plates in R2E (RPMI 1640:Eagle-Hanks’ amino acid medium 
1:1) medium containing 10% autologous plasma. On day 7, 1  106 cul-
tured cells were restimulated with 8  104 irradiated monocyte-derived
dendritic cells pulsed with 0.01 M T1 peptide in a 48-well culture plate.
One day after each restimulation, T cell growth factor (CELLKINES
TCGF, as a source of natural human IL-2 from human lymphocytes; Zep-
tometrix) was added to a final concentration of 10%. Cell lines were main-
tained in R2E containing 10% autologous plasma, 1 mM sodium pyruvate,
nonessential amino acids (Biofluids), 4 mM glutamine, 100 U/ml penicil-
lin, 100 g/ml streptomycin, and 50 M 2-ME. Autologous plasma was
positive for anti-gp120 Abs, but such Abs generally do not affect presen-
tation of peptide Ag bound to class II MHC molecules. After checking the
Ag-specific response, the cell line (KT9) was restimulated every other
week for maintenance using the same conditions as for its original estab-
lishment (with irradiated monocyte-derived dendritic cells pulsed with 0.01
M T1 peptide).
Proliferation assay
T cell proliferation was assessed by culturing 5  104 KT9 cells with 1 
104 autologous monocyte-derived dendritic cells with or without antigenic
peptide in 200 l of R2E medium containing 10% autologous plasma in
96-well U-bottom culture plates for 3 days. KT9 cells were used in a
resting state after 2 wk of rest, just before the next restimulation. (Prolif-
eration assays were done on the same day as, and in parallel with, restimu-
lation of the remaining cells of the line.) Cultures were pulsed with 1 Ci
of [3H]thymidine/well for the last 24 h. Plates were harvested and counted
in a 1205 Betaplate counter (Wallac). All samples were analyzed in trip-
licate, and all experiments were performed at least twice with comparable
results.
IFN- assay
A total of 4 105 KT9 cells and 4 104 monocyte-derived dendritic cells
were cultured with or without peptide at 10 M in 96-well U-bottom plate.
Seventy-two hours later, each supernatant was collected, and IFN- in the
culture supernatant was determined by ELISA kit (R&D Systems) accord-
ing to the manufacturer’s instructions. All samples were analyzed in
triplicate.
Results
The T1-specific CD4 T cell line is restricted to DR13
We developed a T1-specific CD4 T cell line (KT9) from a
healthy volunteer immunized with a canarypox virus vector ex-
pressing HIV gp120. KT9 was determined to be CD4 and
HLA-DR restricted in an inhibition assay using anti-CD4 or anti-
HLA-DR, respectively (Fig. 1A). The HLA-DR haplotype of the
volunteer was DR1*01 and DR1*13. Thus, we tested the
HLA-DR restriction of this helper line using dendritic cells from
the PBMCs of different volunteers sharing one or the other
HLA-DR type. This helper line was restricted to DR1*13, which
is common in U.S. Caucasians and is also one of the major
HLA-DR haplotypes in Africa (21, 22) (Fig. 1B). It should also be
noted that the lack of response to T1 with DR13-negative present-
ing cells clearly rules out a nonspecific mitogenic effect of the T1
peptide, and the lack of response to other peptides shown below in
Figs. 2 and 3B clearly shows that the KT9 line is Ag specific.
Recognition specificity of KT9 using single alanine-substituted
analogues
In a set of experiments to define key functional residues in the T1
peptide, peptides were synthesized with single alanine substitution
for each original amino acid, except using Ser in sites at which Ala
was the natural residue (Table I). All peptides were tested in an
epitope-specific proliferation assay (Fig. 2). Among the 14 ala-
nine- or serine-substituted peptides, substitutions at the first five
positions (peptides 28–40) did not have any effect on the T1-
specific CD4 response. However, the next six substituted peptides
(peptides 40–61, except 49) induced a significantly lower re-
sponse. Furthermore, two alanine-substituted T1 peptides (pep-
tides 64 and 67) showed a slightly better response than the original
peptide. Based on the data of Fig. 2 and of the peptide sequence
motif pattern of DR1*13-restricted peptides (22, 23), we hypoth-
esized that the binding core motif of the T1 peptide in humans is
WQEVGKAMY.
Recognition property of KT9 using substituted peptides in
anchor positions
In general, a typical HLA class II-binding peptide has four anchor
residues within a span of nine residues in positions 1, 4, 6, and 9
from the N-terminal end. In the case of the peptide sequences
presented by DR1*13, hydrophobic residues are preferentially
found at positions 1 and 4. A positively charged residue is fre-
quently present at position 6. A small or hydrophobic residue is
found at position 9 (22, 23). Thus, we next investigated the char-
acteristics of the amino acid fitted to each anchor position of the
postulated T1-binding core peptide using peptides substituted with
amino acids having different chemical properties. First, we used
peptides with a single amino acid substituted in each anchor po-
sition (Fig. 3A). In position 1 (tryptophan in the postulated T1 core
peptide), alanine (small)- and isoleucine (aliphatic)-substituted T1
made the response worse. However, a phenylalanine (aromatic)
substitution did not reduce the response. This result suggested that
an aromatic amino acid is required in position 1. In position 4, the
alanine- and phenylalanine-substituted T1 elicited a poor response
from KT9. However, the isoleucine substitution induced much bet-
ter helper response. This result suggested position 4 as anchor
should be an aliphatic amino acid and isoleucine could enhance the
Ag-specific response of the T1-specific CD4 T cell line. In con-
trast, in position 6, only a positively charged amino acid-substi-
tuted peptide induced a better T1-specific response. The positively
charged arginine (R) at position 6 might be better binding to HLA-
DR1*13 because its pK is higher (12.5 for R vs 10.5 for K).
In position 9, all peptides substituted with small, aromatic, or al-
iphatic amino acids induced a better CD4 response than the orig-
inal peptide. Also, in a titration assay, KT 9 stimulated with the
substituted peptides that had induced the best response in each
anchor position at 10 M showed a better response than with the
original peptide (Fig. 3B). It should be noted that peptides pre-
sented by HLA class II molecules usually need to be longer than
the minimal 9-mer that spans the length of the HLA groove, and
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we do not know the optimal length, which could affect the mag-
nitude of the response. Moreover, we tested and compared peptide-
specific IFN- production of KT9 T cells between the wild-type
T1 and the altered T1 peptide 53. The altered T1 peptide induced
higher IFN- production by KT9 than the wild-type T1 (only pep-
tide 53 was significantly different from the no-Ag control; p 
0.01) (Fig. 3c). This result suggested the epitope-enhanced peptide
could induce not only more active proliferation of the T1-specific
CD4 T cells, but also greater CD4 T cell activation in a Th1 func-
tional response. In other words, these results mean that a CD4
epitope does not always have the most optimal amino acid in each
anchor position required for both binding to the HLA class II mol-
ecule and recognition by a CD4 T cell. At the same time, it
suggests that the peptides with a combination of substitutions in
anchor positions might be able to induce a much better CD4 T
cell response as a vaccine construct.
Antigenic potency of the multiply substituted T1 peptide
Each of three separate point mutations of the T1 peptide, V to I in
position 4, K to R in position 6, and Y to A in position 9, respec-
tively, enhanced the proliferative response of KT9 (Fig. 3). Thus,
we combined all three mutations in the peptide 70 (Table I) and
tested antigenic potency of this multiply substituted peptide in the
proliferation assay (Fig. 4). The peptide concentration in which
KT9 showed the peak proliferative response was shifted to a lower
peptide concentration when using this triple combinational peptide
FIGURE 1. HLA restriction and character of T1-spe-
cific CD4 line (KT9). A, Inhibition assay of KT9. Pro-
liferation of KT9 in response to T1 peptide was inhib-
ited with anti-CD4, CD8, HLA-DR, HLA-DQ, or
control IgG. The concentration of each Ab was 10 g/
ml. B, Proliferation of KT9 against APCs of different
HLA-DR types partially matched with the T cell donor
(DR1* (01, 13)). The haplotypes of HLA-DR used in
this assay were DR1* (01, 13), DR1* (01, 11),
DR1* (04, 13), and DR1* (11, 13). Error bars rep-
resent SEM of triplicate wells, and the experiment was
performed twice with comparable results.
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than the original peptide T1, and the activity remained substan-
tially higher than that of the wild-type peptide at a 10-fold lower
concentration. Note that the high-dose inhibition of T cell prolif-
eration also occurs at lower peptide concentration for the triple
combinational peptide than for T1, again consistent with the shift
in dose-response curve. These results suggested that the epitope-
enhanced peptide that has the best binding capacity in each pocket
in the HLA molecule could induce the best response of the wild-
type specific CD4 T cell. Also, the multiple substitutions in an-
chor positions do not interfere with recognition by the wild-type
specific human CD4 T cell line.
We attempted to assess and rank order the modified and wild-
type peptides as specific stimuli of CD4 T cell proliferation in
PBMCs of four HIV long-term nonprogressing individuals who
had been typed as HLA-DR13 positive (data not shown). Unfor-
tunately, using thymidine incorporation and CFSE dye dilution
detection by flow cytometry, we detected no response to any of the
peptides, including the enhanced substituted peptides, nor to the
full-length IIIB gp120 envelope, in any of several repeated at-
tempts with cells from the four donors. This is consistent with the
published literature describing a rapid and profound loss of CD4
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FIGURE 2. Proliferation of KT9 against T1 variant peptides with ala-
nine substitutions. The concentration of each substituted peptide was 10
M. Each peptide number is listed in Table I. Error bars represent SEM of
triplicate wells, and the experiment was performed twice with comparable
results.
FIGURE 3. Proliferation and IFN- production of KT9 against peptides
substituted in anchor positions. A, The concentration of each substituted
peptide was 10 M. Each peptide number is listed in Table I. The position
of these residues in the original T1 peptide and the corresponding motif
residue preferences (22, 23) are shown below. B, Titration of peptides
53, 59, and 67, and the original T1 peptide in a proliferation assay of
KT9 T cells. Error bars represent SEM of triplicate wells, and the ex-
periment was performed twice with comparable results. C, Comparison
of peptide-specific IFN- production between the wild-type T1 and the
altered T1 peptide 53.
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proliferative response to HIV envelope even among long-term
nonprogressors (24–29).
Discussion
The T1 Ag was the first CD4 helper epitope discovered in the HIV
envelope protein (13, 16, 17). A CD4 response specific for this
epitope could be observed in some HIV-seropositive individuals in
the United States and healthy volunteers vaccinated with gp160 in
Zaire, Africa (16, 17). These facts indicated that the T1 epitope is
obviously presented by some relatively prevalent human HLA
class II molecules. However, the actual class II restriction of T1-
specific CD4 T cells remained yet to be clarified. In this study,
we developed a T1-specific human CD4 T cell line (KT9) from
a healthy Caucasian American volunteer immunized with a ca-
narypox virus vector expressing gp120 and found that this CD4
helper line is restricted to DR1*13 (Fig. 1b). DR13 is one of the
major haplotypes in Africa, where there are 25 million HIV-
infected patients (30), and is also common in U.S. Caucasians as
well as African-Americans (22). Thus, the T1 Ag could be a very
useful CD4 epitope as an HIV vaccine component in North Amer-
ica and Africa. Because HIV epitopes may have evolved to evade
the immune system, we applied epitope enhancement by sequence
modification to increase the potency of this epitope.
To achieve a stronger CD4 T cell response against this T1
epitope, we tested the proliferative response of KT9 against some
amino acid-substituted variants of T1 peptide. Except for two
cases, T1 peptides with alanine substituted in each position could
not induce a stronger proliferative response from KT9 than the
original T1 (Fig. 2). However, we could identify the likely binding
core as WQEVGKAMY based on the alanine substitutions that
diminished recognition, together with proliferation assay data us-
ing truncated peptides of T1 (data not shown). Most HLA-DR-
binding core sequence motifs typically have four anchor residues.
An aromatic amino acid and an aliphatic amino acid are preferen-
tially found in positions 1 and 4, respectively (Fig. 3). Although
the substitution of phenylalanine for tryptophan in position 1 did
not produce a better CD4 response, the substitution of isoleucine
for valine in the T1 peptide increased proliferation of KT 9 up to
2-fold over the original T1-stimulated response. Both valine and
isoleucine belong to the same aliphatic branched chain amino acid
group. This suggests that there might be a hierarchy for binding to
pockets of HLA-DR molecules among amino acids in a same
group. Position 6 is thought to be an allele-specific anchor (31). In
the case of DR13, a positively charged amino acid is preferable.
Also from our data (Fig. 3), a replacement of lysine by the posi-
tively charged amino acid with a higher pK, arginine, in position
6 enhanced the CD4 response. The replacement by this positively
charged amino acid with a higher pK (12.5 vs 10.5 for lysine) in
this allele-specific anchor position might be a broadly applicable
method for epitope enhancement of CD4 epitopes presented by
DR13. However, more confirmation using many different DR13-
binding peptides would be required to confirm the generality of
this approach. It is of interest that although the T1 sequence is
relatively conserved, being in the CD4 binding site, the position 6
residue is essentially always K in clade B viruses, mostly R in
FIGURE 4. Proliferation of KT9 with multiply substituted peptide (70)
and the original T1 peptide. Data represent means of triplicate wells, and
the experiment was performed twice with comparable results.
Table I. Peptides used in this studya
428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443
T1 K Q I I N M W Q E V G K A M Y A
28 - A - - - - - - - - - - - - - -
31 - - A - - - - - - - - - - - - -
34 - - - A - - - - - - - - - - - -
37 - - - - A - - - - - - - - - - -
40 - - - - - A - - - - - - - - - -
43 - - - - - - A - - - - - - - - -
44 - - - - - - F - - - - - - - - -
45 - - - - - - I - - - - - - - - -
46 - - - - - - - A - - - - - - - -
49 - - - - - - - - A - - - - - - -
52 - - - - - - - - - A - - - - - -
53 - - - - - - - - - I - - - - - -
54 - - - - - - - - - F - - - - - -
55 - - - - - - - - - - A - - - - -
58 - - - - - - - - - - - A - - - -
59 - - - - - - - - - - - R - - - -
60 - - - - - - - - - - - E - - - -
61 - - - - - - - - - - - - S - - -
64 - - - - - - - - - - - - - A - -
67 - - - - - - - - - - - - - - A -
68 - - - - - - - - - - - - - - F -
69 - - - - - - - - - - - - - - I -
70 - - - - - - - - - I - R - - A -
a The sequences of T1 and the various substituted analogs are given in single letter amino acid code. Numbers at the top of each column refer to positions in the HIV-1 IIIB
gp160 protein. Dashes in each row indicate that the residue at that position in that peptide is the same as T1.
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clade C viruses, and either K, R, or Q in clade A viruses. All three
of these alternatives can be accommodated in the DR13-binding
motif.
In our previous paper, we showed that an epitope-enhanced HIV
CTL epitope substituted with the appropriate amino acids in all
class I MHC anchor positions can induce a better CTL response in
vitro and in vivo, and further that the anchor-enhanced epitope-
specific CTL can recognize the wild-type epitope with complete
cross-reactivity (32). Other enhanced CTL epitopes from HIV-1
reverse-transcriptase binding better to a class I molecule have been
described (33). However, it is equally important to determine
whether the epitope-enhancement strategy could magnify the ac-
tivation of human HIV-specific CD4 T cells recognizing a pep-
tide binding to a human class II HLA molecule to help the expan-
sion and maintenance for HIV-specific CTLs. Yet, there is little
experience with epitope enhancement for peptides binding human
class II HLA molecules.
The importance of improving the CD4 T cell response as well
as the CD8 T cell response is becoming more apparent as more
is known about the importance of CD4 T cell help in inducing a
long-lived memory CD8 T cell response (5, 7–9, 34). In a mouse
model using a T1 variant with higher affinity for a mouse class II
MHC molecule, we found that this enhanced peptide induced not
only a stronger CD4 T cell response, but shifted the quality of the
response toward Th1 by up-regulating CD40 ligand on the helper
cells and polarizing dendritic cells to make IL-12, and thus shifting
the cytokine profile of the helper cells and inducing a stronger CTL
response to an attached CTL epitope (19, 20). The result was better
protection against viral challenge in the mouse model. Thus, we
tested whether this principle could be true for the epitope enhance-
ment of this human HIV CD4 epitope using KT9.
The multiply substituted peptide 70 shifted the peak prolifera-
tive response of KT9 to lower concentrations (Fig. 4). An epitope-
enhanced peptide also showed a stronger IFN- response (Fig. 3c).
The result suggested that the epitope-enhanced HIV CD4 epitope
substituted with appropriate combinations of anchor residues could
also induce a stronger wild-type specific CD4 T cell response.
However, it will also be important to determine the portion of the
CD4 T cell repertoire specific for the enhanced peptide that cross-
reacts with the wild-type epitope, for example, immunizing hu-
mans with the enhanced peptide, or using HLA-DR13 transgenic
mice, as described in our previous paper on enhancing an HLA
class I-restricted epitope (26). Such an epitope-enhancement strat-
egy could induce stronger CD4 responses in humans that might
provide more effective CD4 T cell-mediated help for CTL main-
tenance against HIV. A similar strategy could be applicable to any
Ag for which an optimal CD4 and CD8 T cell response is
desirable.
Our findings show that modifying this HIV CD4 epitope with
some amino acid substitutions in anchor regions for epitope en-
hancement could magnify the T1-specific CD4 helper response
compared with the original T1 peptide. Of course, enhanced anti-
genicity in vivo may not necessarily translate into enhanced im-
munogenicity in vivo, although it often does. This cannot be de-
termined without a clinical trial, for which this study provides the
preclinical data and motivation. Furthermore, the T1 peptide is just
one of a number of HIV CD4 epitopes. This strategy would be
more effective when applied to multiple conserved CD4 epitopes
in HIV, as well as to HIV CTL epitopes, as we recently described
(32). Also, these studies provide a rational strategy for the con-
struction of enhanced epitopes that can be applied to build the next
generation vaccines, applicable to all forms of vaccine, peptide,
DNA, recombinant viral or bacterial vector, or live attenuated
virus.
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